400 Professional Drive
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
491 articles with Emergent BioSolutions
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has approved the extension of the shelf life of NARCAN® Nasal Spray from 24 months to 36 months.
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 million in aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Notes”). The Notes are fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company has used the
Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the “Notes”), representing an increase of $50 million in aggregate principal amount from the initially proposed offering size.
Emergent BioSolutions Inc. announced that it intends to offer $400 million aggregate principal amount of senior unsecured notes with an expected maturity date of August 2028.
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and six months ended June 30, 2020 and revised upward full year 2020 guidance.
Gaithersburg, Maryland-based Emergent BioSolutions inked another manufacturing agreement to support the development of a vaccine against COVID-19, the disease caused by the novel coronavirus.
Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate
Emergent BioSolutions Inc. announced that it has signed an agreement to provide contract development and manufacturing services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
Emergent BioSolutions Inc. (NYSE: EBS) today announced that Standard & Poor’s (S&P) has indicated that the company will be added to the S&P MidCap 400® index, effective prior to the open of trading on Friday, July 24.
Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
Emergent BioSolutions Inc. will host a conference call on Thursday, July 30, 2020 at 5:00 pm to discuss the financial results for the second quarter of 2020, recent business developments, revenue guidance for the third quarter of 2020, and financial outlook for full year 2020.
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
Emergent BioSolutions Inc. announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology.
Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Emergent BioSolutions announced that it will further strengthen its contract development and manufacturing capabilities by expanding into viral vector and gene therapy.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences this month:
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate
Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate Agreement valued at approximately $87 million GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it will deploy its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZeneca’s vaccine candidate for
Emergent BioSolutions, a contract development and manufacturing organization, announced it had signed a public-private partnership under Operation Warp Speed worth about $628 million.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021